Tag Archives: vaso-occlusive crises

Sanofi’s Rilzabrutinib Granted Fourth Orphan Drug Designation, Now Targeting Sickle Cell Disease

(IN BRIEF) Rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has received orphan drug designation from the U.S. FDA for sickle cell disease. This marks the fourth such designation for the drug, which has already been recognized for its potential … Read the full press release